key: cord-0029956-6u9fyn3l
authors: Siegel, Patrick M.; Przewosnik, Anne-Sophie; Wrobel, Jan; Heidt, Timo; Moser, Martin; Peter, Karlheinz; Bode, Christoph; Diehl, Philipp; Bojti, István
title: An activation specific anti-Mac-1 designed ankyrin repeat protein improves survival in a mouse model of acute lung injury
date: 2022-04-15
journal: Sci Rep
DOI: 10.1038/s41598-022-10090-6
sha: 85d14d67fa32e56fd54c0064532505e6914841de
doc_id: 29956
cord_uid: 6u9fyn3l

The acute respiratory distress syndrome (ARDS) is a life-threatening clinical condition. The number of ARDS cases has risen dramatically recently but specific treatment options are limited. ARDS is associated with an overshooting inflammatory response and neutrophils play a central role in its pathogenesis. Neutrophils express the integrin Mac-1 on their surface which adopts a resting and activated conformation depending on leukocyte activation. The aim of this study was to investigate the anti-inflammatory effects of the unique activation-specific anti-Mac-1 DARPin ‘F7’ in a mouse model of ARDS. ARDS was induced by intratracheal lipopolysaccharide (LPS) instillation and the acute (day 1–4) and chronic phase (day 5–10) were studied. After expression and purification, F7, a control DARPin and PBS, were applied daily via the intraperitoneal route. Survival and weight loss were recorded. Histological analysis of lung sections, flow cytometric leukocyte analysis of blood and bronchioalveolar lavage (BALF) were performed. Moreover, protein concentration and cytokine levels were determined in the BALF. Treatment with F7 improved survival and reduced weight loss significantly compared to treatment with the control DARPin or PBS. Neutrophil count in the BALF and peripheral blood were significantly reduced in mice treated with F7. Histology revealed significantly reduced pulmonary inflammation in the F7 treated group. Treatment with DARPin F7 inhibited neutrophil accumulation, reduced signs of local and systemic inflammation and improved survival in a mouse model of ARDS. F7 may be a novel anti-inflammatory drug candidate for the treatment of severe ARDS.

The acute respiratory distress syndrome (ARDS) is a life threatening clinical condition characterized by severe acute hypoxemia and bilateral radiological opacities, which develop within one week and are not fully explained by cardiac failure or fluid overload 1, 2 . ARDS may be triggered by several causes, the most common being trauma, aspiration, extrapulmonary sepsis or pneumonia 1, 3 . ARDS has moved to the center of public and scientific attention due to the ongoing SARS-CoV-2 pandemic. Mortality due to ARDS remains high as therapeutic options are limited to the treatment of the underlying condition, if possible, and supportive therapy including, fluid management (diuretics) mechanical ventilation and extracorporeal membrane oxygenation 2,4-6 . Consequently, there is an urgent need for novel therapeutic strategies 7 .

Neutrophils play a central role in the pathogenesis of ARDS 8 . The leukocyte integrin Mac-1, which is highly expressed on neutrophils, is crucial for leukocyte migration through the endothelium rendering it an attractive therapeutic target 9 . Mac-1 adopts a resting and activated conformation, both with distinct functions 10 .

Designed Ankyrin Repeat Proteins (DARPins) are a novel class of binding proteins with multiple advantages over antibody drugs 11 . Compared to conventional immunoglobulins, DARPins bind to their targets with similar or even higher affinity but offer several advantages such as higher stability and cost-effective production 12, 13 . We recently assessed the anti-inflammatory effects of a unique activation-specific anti-Mac-1 DARPin 'F7' in mouse models of myocarditis, sepsis and myocardial infarction 14 .

A realistic and highly reproducible mouse model of the acute lung injury (ALI) is the intrapulmonary lipopolysaccharide (LPS) application 15 . Intratracheal administration of LPS leads to reliable neutrophil accumulation, alveolar wall thickening, protein-rich edema and detritus in the alveolar space 16 .

The aim of this study was to find a novel anti-inflammatory treatment option for ARDS. For this purpose, the therapeutic effects of the activation-specific anti-Mac-1 DARPin 'F7' were assessed in a mouse ARDS model of intrapulmonary LPS application.

The experimental protocols were approved by the responsible local authorities ('Regierungspräsidium Freiburg' , .81/G-19/122). Only male mice were used. The mouse model of acute lung injury consists of the acute and chronic phase (Fig. 1) . Four treatment groups were formed (healthy controls, PBS, control DARPin, F7). Mice within a treatment group were pre-assigned to the 'acute' (day [1] [2] [3] [4] or 'chronic' (day 5-10) phase before application of LPS (No. of mice in the acute phase: healthy controls: 5, control DARPin: 19, F7: 11, PBS: 17). To comply with our animal ethics approval, the lowest number of mice per treatment group and phase needed to show significant differences was chosen taking into account the expected survival rate in the literature 17 . Several mice in each treatment group (and particularly the control groups) including mice pre-assigned to the chronic phase had to be euthanized early as they reached criteria for early euthanasia (Table 1) . These mice were then switched to the acute phase. On day 4, the remaining mice originally assigned to the acute phase, that had not suffered extreme weight loss were euthanized. The remaining mice in each group were euthanized on day 10 and were part of the 'chronic phase' . 4-6 mice in each treatment group had to be excluded from analysis post-hoc as they did not develop weight loss at all and application of LPS had most likely been intragastric. Acute phase. The first 4 days after endotracheal application of LPS were considered the acute phase of acute lung injury. 15 of the PBS treated, 2 of the F7 treated and 15 of the control DARPin treated animals reached the criteria for euthanasia (as defined in the "Methods" section) and were euthanized early (on day 2 or 3). A total of 17 mice in the PBS group, 19 mice in the control DARPin group and 11 mice in the F7 group were counted towards the acute phase and blood, BALF and lung tissue were analyzed. All healthy animals (no LPS treatment) survived. DARPin F7 improves survival. As described in the "Methods" section, animals were euthanized if they developed weight loss over 20% or if they exhibited signs of massive distress. Mice that survived until day 4 were considered as survivors. Survival was improved in the group treated with F7 ( Fig. 2 The number of mice per treatment group was determined according to the expected survival rate and the number of mice needed to show significant differences. Mice were pre-assigned to the acute or chronic phase. Planned euthanasia was conducted on day 4 (acute phase) or day 10 (chronic phase). Mice were euthanized early if they showed signs of severe weight loss or distress (Table 1 ) and were then counted as non-survivors. Several mice in the PBS and control DARPin group which were pre-assigned to the chronic phase had to be sacrificed early as they reached criteria for euthanasia. Fig. 4 ). The level of monocytes (CD45 + CD11b + Ly6C + Ly6G − ) in the BALF were significantly reduced in the group treated with F7 compared to the PBS group (monocyte count/ ml PBS vs. F7: 1276 ± 240.3 vs. 441 ± 87.33 p = 0.008). As previously described, levels of B-Lymphocytes and T-lymphocytes in the BALF were extremely low and are therefore not presented 17 . DARPin F7 prevents the elevation of protein content in the BALF. The protein content in the BALF can be used as a marker of pulmonary inflammation and was therefore determined. Protein content of the BALF was significantly elevated in the groups treated with PBS and the control DARPin compared healthy control animals or those treated with F7 (Protein concentration in mg/dl PBS vs. control DARPin vs. healthy controls vs. F7: 0.77 ± 0.08 vs. 0.62 ± 0.09 vs. 0.16 ± 0.04 vs. 0.3 ± 0-04, p < 0.001 for F7 vs PBS, p = 0.011 F7 vs. control DARPin; Fig. 4 ). Table 1 . Criteria for euthanasia. According to the Society of Laboratory Animal Science 47 , the following criteria were controlled on every day of the experiment. If one of them was fulfilled, the mouse was euthanized. (occurrence is signalized as percentage of all prematurely euthanized animals).

Weight loss ≥ 20% compared to the start weight (100%)

Tachy-/bradypnea with use of accessory breathing muscles (90.6%)

Severe disturbance in coordination ( (Table 1) . Probability of survival was calculated by dividing the number of surviving mice by the number of total mice (acute and chronic phase) and multiplying the result with 100%. The survival probability was significantly increased for mice treated with F7 compared to the PBS or the control DARPin groups. Data are presented as mean ± SEM. n = 10-35 per group, **p < 0.01, ***p < 0.001. Comparisons of overall survival were performed using the log-rank test. (b) Mean weight over time during the acute and chronic phase of the mouse model of acute lung injury. Mice treated with the control DARPin or PBS suffered more severe weight loss compared to mice treated with F7, particularly during the acute phase, as exemplified on day 3. Data are presented as mean ± SEM. n = 10-35 mice per treatment group, *p < 0.05, ***p < 0.001, Body weight on day 3 was compared using an unpaired t-test. Figure S3 ). There was a significant reduction of the IL-6 and IL-10 expression in the lung tissue of mice treated with F7 compared to PBS and a marked reduction in the IL-6 and IL-10 expression in the lung tissue of mice treated with F7 compared to control DARPin (mRNA expression fold change: IL-10: www.nature.com/scientificreports/ Neutrophils and monocytes were analyzed by flow cytometry as described in the "Methods" section. Protein content in the BALF was determined using a BCA assay. Absolute cell counts were determined using Trucount beads following the manufacturer's instructions. (a) Animals treated with DARPin F7 had significantly lower neutrophil counts in the BALF than the PBS or control DARPin treated groups. Compared to healthy control animals, neutrophil counts were elevated in all treatment groups. (b) Monocyte counts in the BALF were also significantly reduced in the F7 treated group compared to the PBS treated group. Again, monocyte counts were elevated in all treatment groups compared to healthy controls. (c) The protein concentration in the BALF was significantly higher in mice receiving PBS or the control DARPin compared to mice treated with F7. Data are presented as mean ± SEM. n = 5-19, *p < 0.05, **p < 0.01, ***p < 0.001. Treatment groups were compared by an unpaired t-test. Figure S4) Chronic phase of acute lung injury. The chronic phase of ALI was investigated in animals that survived until day 10 after LPS introduction. 5 healthy control animals, 5 mice receiving PBS, 8 treated with F7 and 10 control DARPin treated animals were analyzed.

Body weight and peripheral blood leukocyte counts are similar in all treatment groups. Animal weight was similar in all treatment groups during the chronic phase. Moreover, flow cytometric analysis revealed that peripheral leukocyte blood counts did not differ significantly between the F7, control DARPin or PBS treated groups (Fig. 6) . (c) Percentages of T-cells were significantly higher in the healthy control group compared to the F7 treated group. There was no significant difference between the other treatment groups. (d) No significant differences were observed regarding the percentage of B-cells between the different treatment groups and compared to healthy controls. Data are presented as mean ± SEM. n = 5-10, *p < 0.01. Treatment groups were compared by an unpaired t-test. (Fig. 7) .

BALF protein content and histology is similar in all treatment groups in the chronic phase. All groups receiving intratracheal LPS had similar total protein levels in the BALF on day 10 with no significant differences between treatment groups (Fig. 7) . Furthermore, there were no significant differences in the histological scores between treatment groups on day 10 (Fig. 8 ).

In this study we demonstrate that the anti-Mac-1 DARPin F7 significantly inhibits the local and systemic inflammatory reaction and improves survival in a mouse model of ARDS. ARDS is associated with high mortality rates and treatment is challenging and prolonged. A therapeutic agent, which inhibits or mitigates the development and course of the disease is urgently required.

We demonstrate that treatment with DARPin F7 reduces neutrophil infiltration into the alveoli and the percentage of neutrophils in the peripheral blood. This finding is important as neutrophils play a central role in the initiation and progression of ARDS. For example, Abraham et al. describes, that the activation and accumulation of neutrophils in the lungs is one of the first steps in the development of ARDS 18 . Moreover, there are only few cases of ARDS in patients with neutropenia 19 . Additionally, multiple studies demonstrated, that lung infiltrating neutrophils are the main cell type in the BALF in patients with ARDS [20] [21] [22] . ARDS is characterized by the injury of the alveolar endothelium (pulmonary ARDS) or the microvascular endothelium (extrapulmonary ARDS), leading to a severe inflammation of lung tissue. Irrespective of the origin, this results in interstitial and alveolar edema and a mainly neutrophil driven elevation of inflammatory mediators 2 .

We also demonstrated, that treatment with F7 reduces the intrapulmonary expression of the cytokines IL-6 and IL-10, which, according to several studies, are predictive of poor outcome in ARDS, if elevated [23] [24] [25] . In this line of evidence, we report significantly reduced cytokine levels in the BALF in mice treated with F7 compared to mice treated with the control DARPin and PBS. As expected, the pro-inflammatory cytokines IL-1β, TNF-α, IFN-γ, IL-6 were significantly reduced in the F7 group underlining its strong anti-inflammatory effects. The decreased local inflammatory response may be one of the contributing factors to improved survival observed in the F7 group. We also found significantly reduced levels of IL-12 in the BALF in mice treated with F7. IL-12 promotes the release of vascular endothelial growth factor, which in turn increases vascular permeability 26, 27 . By reducing IL-12 levels, F7 may therefore improve the endothelial barrier function leading to reduced pulmonary edema and an attenuated local inflammatory response. Lower MCP-1 levels in the BALF, which we report for the F7 group, have also been associated with a dampened local inflammatory response after treatment in mouse models of LPS-induced acute lung injury 28, 29 .

In the clinic, not only the neutrophil count in the BALF, but also the neutrophil-to-lymphocyte ratio in peripheral blood is an important prognostic factor in patients with ARDS 30 . In this line of evidence, our study www.nature.com/scientificreports/ demonstrated a significant reduction in the percentage of neutrophils in the peripheral blood in mice treated with F7 compared to PBS or the control DARPin. Furthermore, this effect can be regarded as evidence of a reduced systemic inflammatory reaction in the F7 treated animals 31 . The percentage of blood neutrophils is often increased in animals experiencing stress 31 . Consequently, the percentage of neutrophils was significantly increased in the blood of all LPS-treated mice compared to healthy mice. As we quantified leukocyte subpopulations as percentage of total leukocytes, the lower percentages of lymphocytes observed in the LPS treated groups compared to healthy controls most likely reflect the proportional increase of neutrophils in the LPS-treated groups and not lymphocyte migration.

In the chronic phase, the percentage of blood neutrophils was substantially, yet not significantly increased in mice treated with F7 compared to those treated with the control DARPin or PBS. Most likely, this finding is coincidental since the elevated mean percentage of neutrophils in the F7 group is strongly influenced by one mouse with a neutrophil percentage of 59% which is much higher than in the other F7 treated mice. However, this mouse was included in our analysis as it was not identified as an outlier using the statistics described in the "Methods" section.

To fulfil their central role in the development of ARDS, neutrophils need to be activated and migrate into the lung 18 . Mac-1 on the neutrophil surface is the main mediator of neutrophil migration during experimental LPS induced murine ARDS 32 . We previously demonstrated that DARPin F7 binds preferentially to activated neutrophils which are highly pro-inflammatory 14 . This characteristic of F7 has the potential to reduce inflammation in a highly specific manner while avoiding severe immunosuppression since only activated neutrophils are targeted. Furthermore, protein modifications (e.g. albumin binding domains, PEGylation) can be used to bioengineer the serum half-lives of DARPins from days to weeks enabling an effective period as needed and shortening the period of immunosuppression 33 .

Mac-1 has previously been targeted for therapeutic purposes in mouse models of acute lung injury 32, 34 . Although local inflammation was reduced, survival data was not presented. Our data, however, shows that activation-specific anti-Mac-1 treatment with DARPin F7 not only reduces inflammation but also improves survival. Our results are likely to have been favored by the inherent properties of F7. For example, due to its smaller size compared to immunoglobulins (17 kD vs. approx. 150 kD) DARPins can penetrate deeper into tissue and local areas of inflammation. Additionally, DARPins are highly stable and can be produced and purified relatively easily at high yields leading to low costs 11 . Moreover, DARPins have been shown to be safe for systemic application in humans and phase II trials are currently ongoing investigating the effects of DARPin MP0250 against multiple myeloma 35 . www.nature.com/scientificreports/ Conventional non-activation specific anti-integrin antibodies were used in previous animal studies of acute lung injury. However, non-activation-specific targeting of integrins has been associated with severe complications. For example, efalizumab, which targets the α L β 2 integrin, was initially approved for the treatment of psoriasis but later removed from the market after multiple cases of progressive multifocal encephalopathy 36 . Another example is abciximab, which targets the α IIb β 3 integrin, effectively inhibits platelet aggregation during percutaneous coronary interventions in cases of myocardial infarction. However, it is associated with severe thrombocytopenia and uncontrolled bleeding complications 37 . Studies have shown that, in the case of α IIb β 3 , effective antithrombotic treatment can be achieved while minimizing bleeding complications by targeting only the activated conformation of α IIb β 3 using a single chain antibody 38 .

A mouse model of ARDS used to investigate novel treatment options should be as similar as possible to human ARDS. Matute-Bello et al. previously published an official workshop for the American Thoracic Society aiming to standardize read-outs for animal models of ARDS 16 . According to these suggestions, histological evidence of tissue injury, the alteration of the alveolar capillary barrier, and the inflammatory response in the BALF were determined as the three main features of experimental ALI. We followed these recommendations in analyzing histological sections of mice with experimental ALI. We used a well-established model of murine ARDS: intratracheal instillation of LPS. This model produces similar pathological characteristics as observed in human ARDS including microvascular and alveolar damage, intrapulmonary hemorrhage, edema and fibrin deposition 39 . These characteristic features were observed by animals which received LPS intratracheally but did not receive F7 i.p. indicating that ARDS was in fact induced. In accordance with the findings of Card et al., who demonstrated significant sex differences by the LPS induced murine ARDS, we only used male mice 40 .

Moreover, an advantage of our model is that it is robust and highly reproducible 39 . This is exemplified by the similar survival and body weight curves of the LPS-treated animals compared to previous studies using this model 41, 42 . However, no murine model can completely mimic the complexity and various etiologies of human ARDS.

In this study we administered the first dose of DARPin F7 and control substances on the day of LPS instillation. Our data indicates that treating ARDS in its early stages before it reaches its peak severity might carry several advantages. In the clinic this is not impractical as it may take several days up to one week for ARDS to develop after an inciting event, for example, viral infection 1, 43 . However, future studies will have to investigate whether delayed treatment with F7 is effective in established ARDS. This is not unlikely, since F7 targets activated neutrophils, and increased levels of neutrophils are reported in the BALF of patients with ARDS on day 7 and 14 44 .

This study is not without limitations. Recently, we demonstrated that DARPin F7 is an effective anti-inflammatory treatment in the cecal ligation and puncture sepsis model which is also a neutrophil driven disease 14 . Therefore, an anti-inflammatory effect was to be expected in the neutrophil driven model of acute lung injury. Moreover, detailed mechanisms of F7's effects are not investigated in this study. As we did not analyze absolute leukocyte counts in whole blood and only present relative changes, we cannot with certainty infer how DARPin treatment affected absolute blood leukocyte blood counts.

In conclusion, we demonstrate that early treatment with DARPin F7 inhibited neutrophil accumulation, reduced signs of local and systemic inflammation and improved survival in our murine model of ARDS. F7 may therefore be a novel anti-inflammatory drug candidate for the treatment of severe ARDS but future studies are required to determine its true potential.

DARPin which does not bind to any known target and has previously been used as a control DARPin in animal experiments 45 . DARPin production and purification and testing were performed as described previously 14 . Expression vectors contained a T5 promotor enabling strong expression of DARPins in E. coli cells using Isopropyl-β-D-thiogalactopyranosid (IPTG). Furthermore, the vectors encode for ampicillin resistance, allowing selective growth in ampicillin-containing media. DARPins contained an albumin binding domain, which is leads to a DARPin half-life in vivo of approximately 1-2 days 33 . DARPins were produced in E. coli BL21 DE3 using LB medium containing ampicillin (F c = 100 µg/ml). Expression was induced by IPTG when the OD 600 reached 0.4-0.7 as determined by a spectrophotometer. After 5 h, cells were harvested by centrifugation and stored at -80 °C. Frozen bacterial pellets were lysed with Bugbuster Mastermix (Merck, Germany) following the manufacturer's instructions and DARPins were allowed to bind to Ni-NTA agarose (Qiagen, Germany) for 1.5 h at RT. DARPins contained a 6 × His Tag allowing purification by Ni + -containing agarose beads. After incubation, Ni-NTA agarose was washed with buffers containing low concentrations of imidazole (10 and 20 mM). DARPins were then eluted with a buffer containing high concentrations (250 mM) of imidazole and dialyzed against PBS for at least 24 h to remove imidazole. Endotoxins were removed by phase separation using Triton X-114 (Sigma-Aldrich, USA) following standard protocols. Protein concentrations were determined using the Pierce™ BCA Protein Assay Kit (Thermo Fisher, USA). DARPin functionality was determined using flow cytometry.

Mouse model of acute lung injury by endotracheal LPS instillation. 8-10 weeks old male C57BL/6 J mice were purchased from Janvier Labs (Le Genest-Saint-Isle, France). All animals had free access to drinking water and food and were kept in the facilities of the Center for Experimental Models and Transgenic Service, Freiburg, Germany. All experiments were conducted strictly according to the German animal protection law and in accordance with good animal practice as defined by the Federation of Laboratory Animal Sci- www.nature.com/scientificreports/ ence Associations (www. felasa. eu) and the national animal welfare body GV-SOLAS (www. gv-solas. de). The study was carried out in compliance with the ARRIVE guidelines. The experimental protocols were approved by the responsible regional authorities ('Tierversuchskomission Regierungspräsidium Freiburg' 35-9185.81/G-19/122). Animals were divided into four groups (Fig. 1) . Three groups received LPS intratracheally (ALI groups) while the healthy control group received PBS only. LPS was purchased from Sigma-Aldrich (St. Louis, USA). The intratracheal instillation was performed under isoflurane anesthesia. Animals in the ALI groups received LPS (5 mg/kg) dissolved in 50 µl PBS intratracheally. Healthy control animals received the same volume of PBS only intratracheally. Animals were treated with 200 µg DARPin F7, control DARPin or PBS daily. Treatments were applied intraperitoneally (i.p.). The first application of DARPins or PBS was performed directly before the intratracheal LPS/PBS instillation (day 0). Animals were checked daily for signs of distress and weighed on day 0, 3, 6, 9 and before euthanasia. According to the protocol, mice were euthanized by exsanguination under ketamine (100 mg/kg)/xylazine (5 mg/kg) narcosis on day 4 for the acute phase groups and on day 10 for the chronic phase groups. Animals were euthanized before this time point if they lost more than 20% of their initial body weight or showed signs of extreme distress (Table 1) . Mice surviving until day 4 were counted as survivors. Probability of survival was calculated by dividing the number of surviving mice by the number of total mice (acute and chronic phase) and multiplying the result with 100%. Bronchoalveolar lavage. Bronchioalveolar lavage (BALF) sampling was performed as described elsewhere 46 . Briefly, the trachea was visualized, and a 26 G catheter was inserted. The left main bronchus was ligated to preserve the lung for histological analysis. The right lung was filled with 0.5 ml sterile PBS three times and approximately a total of 0.6 ml BALF could be aspirated. Samples were centrifugated (2500g, 5 min) and the cell pellet was resuspended in 100 µl PBS. The resuspended pellet was analyzed by flow cytometry and the total protein concentration of the supernatant was determined using the Pierce™ BCA Protein Assay Kit.

Flow cytometry. Leukocyte distribution and concentrations in the BALF were determined using multicolor flow cytometry. DARPins contain a His-tag allowing detection by a secondary Alexa Fluor 488 anti-Histag antibody. The resuspended cell pellet was stained with antibodies solved in PBS supplemented with 0.5% bovine serum albumin (BSA). A master mix was prepared and 10 µl of the master mix was added per sample. The following antibodies were used to prepare the master mix: BV 510 anti-CD45.2, PE-Cy7 anti-CD19, PerCP-Cy5.5 anti-CD3, PE anti-Ly6G, APC anti-SiglecF (APC) and an Alexa Fluor 488 anti-His-tag antibody (all from Biolegend, USA), PE Texas Red anti-CD11b (Thermo Fisher, USA) and V450 anti-Ly6C (BD Biosciences, USA). Absolute cell counts in the BALF were determined using Trucount™ tubes (BD, USA) following the manufacturer's instructions.

Histology and lung injury scoring system. The left lung was filled with OCT compound diluted in PBS.

After fast freezing, 8 µm thick tissue sections were prepared and stained with hematoxylin and eosin according to standard protocols. Histological scoring was performed in a blinded manner following the lung injury scoring system previously described by Matute-Bello et al. 16 (Table 2 ). According to Matute-Bello et al., the main features of experimental ALI include histological evidence of tissue injury, alteration of the alveolar capillary barrier, presence of an inflammatory response, and evidence of physiological dysfunction. Ten fields of vision were analyzed. The number of neutrophils in the alveolar (A) and interstitial space (B), the amount of hyaline membranes (C) and proteinaceous debris (D), as well as the degree of alveolar septal thickening (E) were quantified and given individual scores ( Table 2 ). The independent variables were weighted, and a lung injury score was calculated using the following formula: Score = [(20 × A) + (14 × B) + (7 × C) + (7 × D) + (2 × E)]/ (number of fields × 100).

Quantitative real-time polymerase chain reaction (qRT-PCR). RNA was extracted from frozen murine lungs using Qiazol and RNeasy Mini Kit (Qiagen, Valencia, CA, USA) according to the manufacturer's instructions. Quantitative TaqMan-PCR was performed using a Bio-Rad CFX96 Touch Real-Time PCR System and TaqMan probes Mm00446190_m1 (IL6), Mm01288386_m1 (IL10). Data were analyzed using the 2 −∆∆Ct method. mRNA levels were normalized using GAPDH as a housekeeping gene and then standardized to the mean value of the respective healthy control group. Table 2 . Histological scoring of lung sections. The score for each animal was calculated as follows = [(20 × A) + (14 × B) + (7 × C) + (7 × D) + (2 × E)]/(number of fields × 100). www.nature.com/scientificreports/ Cytokine analysis. Cytokine levels in the BALF from the acute phase were analyzed flow-cytometrically using a commercially available bead-based kit (Legendplex™, Biolegend, USA) following the manufacturer's instructions with the following exceptions. Samples were not-pre diluted, no Matrix-C was used and the incubation with beads was performed over night at 4 °C.

Statistics. Data are presented as mean ± standard error of the mean (SEM). A Kolmogorov-Smirnov test was performed to test for normal or lognormal distribution. Data with lognormal distribution was log-transformed. Outliers were detected with ROUT method (Q = 1%). A two-tailed Student's t-test was used when means of two groups were compared. Survival curves were compared by a log rank test. Statistics were performed using GraphPad Prism V9.0.1 software (GraphPad, USA). A p value ≤ 0.05 was considered statistically significant. *p < 0.05, **p < 0.01, ***p < 0.001.

Ethics approval and consent to participate. All animal studies were approved by the responsible regional authorities ('Regierungspräsidium Freiburg').

The datasets generated and analyzed in this study are available from the corresponding author upon reasonable request.

Received: 30 June 2021; Accepted: 1 April 2022

The Berlin definition

Acute lung injury and acute respiratory distress syndrome

Early identification of patients at risk of acute lung injury

Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome

Fluid management in ARDS: an evaluation of current practice and the association between early diuretic use and hospital mortality

Etiologies, diagnostic work-up and outcomes of acute respiratory distress syndrome with no common risk factor: a prospective multicenter study

The acute respiratory distress syndrome: from mechanism to translation

Pathophysiology of acute lung injury and the acute respiratory distress syndrome

Monocyte trafficking across the vessel wall

Chronology of histological lesions in acute respiratory distress syndrome with diffuse alveolar damage: a prospective cohort study of clinical autopsies

DARPins: A new generation of protein therapeutics

Folding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteins

Designed ankyrin repeat proteins (DARPins): Binding proteins for research, diagnostics, and therapy

A DARPin targeting activated Mac-1 is a novel diagnostic tool and potential anti-inflammatory agent in myocarditis, sepsis and myocardial infarction

Mouse models of acute respiratory distress syndrome: A review of analytical approaches, pathologic features, and common measurements

An Official American Thoracic Society Workshop Report: Features and measurements of experimental acute lung injury in animals

Initiation of LPS-induced pulmonary dysfunction and its recovery occur independent of T cells

Neutrophils and acute lung injury

Adult respiratory distress syndrome in patients with severe neutropenia

Evaluation of bronchoalveolar lavage fluid from ARDS patients with regard to apoptosis

Bronchoalveolar lavage fluid protein expression in acute respiratory distress syndrome provides insights into pathways activated in subjects with different outcomes

Lower airways inflammation in patients with ARDS measured using endotracheal aspirates: a pilot study

Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19

IL-6-based mortality risk model for hospitalized patients with COVID-19

Association of serum interleukin-6, interleukin-8, and Acute Physiology and Chronic Health Evaluation II score with clinical outcome in patients with acute respiratory distress syndrome

Interleukin 12 upregulates the release of vascular permeability factor by peripheral blood mononuclear cells from patients with lipoid nephrosis

Dimethylarginine dimethylaminohydrolase II overexpression attenuates LPS-mediated lung leak in acute lung injury

Effects of a soluble epoxide hydrolase inhibitor on lipopolysaccharide-induced acute lung injury in mice

Cannabidiol, a non-psychotropic plant-derived cannabinoid, decreases inflammation in a murine model of acute lung injury: Role for the adenosine A2A receptor

The association between the neutrophil-to-lymphocyte ratio and mortality in patients with acute respiratory distress syndrome: A retrospective cohort study

The use of leukocyte profiles to measure stress in vertebrates: A review for ecologists

CD11b and intercellular adhesion molecule-1 are involved in pulmonary neutrophil recruitment in lipopolysaccharide-induced airway disease

Half-life extension using serum albumin-binding DARPin® domains

A role for the beta2 integrin CD11b in mediating experimental lung injury in mice

First-in-human phase I study of MP0250, a first-in-class DARPin drug candidate targeting VEGF and HGF, in patients with advanced solid tumors

Assessing long-term drug safety: Lessons (Re) learned from raptiva

Targeting integrin and integrin signaling in treating thrombosis

Targeting ligand-induced binding sites on GPIIb/IIIa via single-chain antibody allows effective anticoagulation without bleeding time prolongation

Acute lung injury induced by lipopolysaccharide is independent of complement activation

Gender differences in murine airway responsiveness and lipopolysaccharide-induced inflammation

Protective effects of patchouli alcohol isolated from Pogostemon cablin on lipopolysaccharide-induced acute lung injury in mice

Therapeutic effects of human umbilical cord-derived mesenchymal stem cells in acute lung injury mice

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China

Evolution of bronchoalveolar cell populations in the adult respiratory distress syndrome

In vivo binding and retention of CD4-specific DARPin 57.2 in Macaques

Bronchoalveolar Lavage of Murine Lungs to Analyze Inflammatory Cell Infiltration

Möglichkeiten der Belastungsbeurteilung im Tierversuch

The authors would like to thank Dr. Klaus Kaier for his support of this project. Timo Heidt is part of the CRC1425. We would like to acknowledge the Lighthouse Core Facility for their assistance with microscopy and FACS analysis. 

Open Access funding enabled and organized by Projekt DEAL. This work was funded by institutional grants of the University of Freiburg.

The authors declare no competing interests.

The online version contains supplementary material available at https:// doi. org/ 10. 1038/ s41598-022-10090-6.Correspondence and requests for materials should be addressed to I.B.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.